Valuation: Prostatype Genomics AB

Market Cap 65.95M 6.53M 5.92M 5.47M 4.94M 9.32M 610M 9.68M 26.09M 329M 24.49M 23.97M 1.04B P/E 2024
-0.38x
P/E 2025 -0.23x
Enterprise Value 62.18M 6.15M 5.59M 5.16M 4.66M 8.79M 575M 9.13M 24.6M 310M 23.09M 22.6M 980M EV / Sales 2024
327x
EV / Sales 2025 23.6x
Free-Float
84.84%
Yield 2024 *
-
Yield 2025 -
1 day-4.61%
1 week-6.57%
Current month-15.35%
1 month-9.00%
3 months-12.50%
6 months-86.96%
Current year-69.67%
1 week 0.09
Extreme 0.088
0.1
1 month 0.09
Extreme 0.088
0.11
Current year 0.08
Extreme 0.0788
2.28
1 year 0.08
Extreme 0.0788
2.28
3 years 0.08
Extreme 0.0788
240
5 years 0.08
Extreme 0.0788
12,000
10 years 0.08
Extreme 0.0788
18,400
Manager TitleAgeSince
Chief Executive Officer - 01/01/2017
Director of Finance/CFO - 31/10/2023
General Counsel - 01/03/2023
Director TitleAgeSince
Chairman - 01/01/2017
Director/Board Member - 01/01/2018
Director/Board Member 74 01/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
-4.61%-6.57%-83.92%-99.87% 6.53M
-3.32%-7.35%+6.42%+21.51% 110B
-2.97%-3.89%+1.72%+95.79% 105B
-1.57%-12.13%+31.53%+412.90% 41.68B
-0.64%+0.73%+10.26%+97.14% 33.35B
-0.19%-1.38%+41.28%+73.88% 29.9B
+0.61%-0.28%+39.20%+91.30% 28.2B
-2.36%-5.82%+42.96%+324.80% 22.45B
-1.37%-2.56%-18.66%-20.58% 19.79B
-0.50%+2.33%-3.41%+33.11% 17.18B
Average -1.72%-2.04%+6.74%+103.00% 41B
Weighted average by Cap. -2.11%-2.28%+13.31%+110.74%

Financials

2024 2025
Net sales 199K 19.69K 17.88K 16.51K 14.9K 28.13K 1.84M 29.2K 78.71K 993K 73.89K 72.33K 3.14M 594K 58.78K 53.36K 49.3K 44.47K 83.96K 5.49M 87.17K 235K 2.96M 221K 216K 9.36M
Net income -41.05M -4.06M -3.69M -3.41M -3.07M -5.8M -380M -6.02M -16.24M -205M -15.24M -14.92M -647M -44.5M -4.4M -4M -3.69M -3.33M -6.29M -411M -6.53M -17.6M -222M -16.52M -16.18M -702M
Net Debt -9.35M -926K -840K -776K -700K -1.32M -86.48M -1.37M -3.7M -46.67M -3.47M -3.4M -147M -3.77M -373K -339K -313K -282K -533K -34.84M -553K -1.49M -18.8M -1.4M -1.37M -59.4M
Projected Income Statement - Annual - Prostatype Genomics AB
Logo Prostatype Genomics AB
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Employees
7
Date Price Change Volume
19/11/26 SEK 0.0910 -4.61% 2,040,466
17/11/26 SEK 0.0954 -0.42% 1,213,406
16/11/26 SEK 0.0958 +0.84% 1,364,732
13/11/26 SEK 0.0950 +2.15% 962,304
12/11/26 SEK 0.0930 -4.52% 2,132,417
  1. Stock Market
  2. Stocks
  3. PROGEN Stock